Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Crossref DOI link: https://doi.org/10.1007/s13402-015-0218-8
Published Online: 2015-02-11
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gotink, Kristy J.
Rovithi, Maria
de Haas, Richard R.
Honeywell, Richard J.
Dekker, Henk
Poel, Dennis
Azijli, Kaamar
Peters, Godefridus J.
Broxterman, Henk J.
Verheul, Henk M. W.
License valid from 2015-02-11